Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3.00M | $0.00 | $589K | $39.9M | $19.0M | $11.0M | $14.2M |
| Revenue growth | — | — | — | — | -100.0% | — | 6665.7% | -52.2% | -42.3% | 29.1% |
| Operating income | -$16.4M | -$17.4M | -$20.5M | -$4.19M | -$20.0M | -$22.7M | $18.2M | -$10.6M | -$62.1M | -$38.6M |
| Operating margin | — | — | — | -139.8% | — | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Net income | -$9.31M | -$25.3M | -$14.4M | -$6.17M | -$24.6M | -$56.7M | $17.9M | -$9.99M | -$57.5M | -$49.6M |
| Net margin | — | — | — | -205.6% | — | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (diluted) | -$0.43 | -$0.92 | -$5.25 | -$2.17 | -$5.28 | -$3.82 | $0.87 | -$0.46 | -$2.15 | -$0.80 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.2M | -$15.4M | -$18.8M | -$3.59M | -$6.80M | -$19.4M | $14.3M | -$1.11M | -$25.6M | -$35.3M |
| Capital expenditures | — | — | — | $25.0K | $0.00 | — | — | — | — | — |
| Free cash flow | — | — | — | -$3.62M | -$6.80M | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.6M | $8.90M | $8.74M | $1.54M | $16.4M | $24.5M | $42.6M | $50.5M | $30.3M | $45.1M |
| Total assets | $21.0M | $28.3M | $16.0M | $1.78M | $17.7M | $26.1M | $49.0M | $53.9M | $36.9M | $50.2M |
| Total liabilities | $3.99M | $11.5M | $5.48M | $9.34M | $31.1M | $3.85M | $2.75M | $4.04M | $11.3M | $34.9M |
| Long-term debt | — | — | — | — | — | — | — | — | $0.00 | $1.13M |
| Shareholders' equity | $17.1M | $16.8M | -$1.70M | -$7.56M | -$13.5M | $22.2M | $46.2M | $49.9M | $6.72M | $15.3M |
| Retained earnings | -$115M | -$140M | -$155M | -$8.05M | -$32.7M | -$89.4M | -$71.5M | -$81.5M | -$139M | -$189M |
| Shares (wtd avg diluted) | 23.7M | 31.7M | 3.12M | 2.85M | 4.66M | 14.9M | 20.6M | 21.6M | 26.7M | 62.2M |
Every figure is extracted from Opus Genetics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.